Effect of enhancer of zeste homolog 2 inhibitor GSK126 on the proliferation and apoptosis of tongue squamous cell carcinoma

doi:10.7518/hxkq.2020.05.004

Abstract

Abstract:

Objective This study aims to study the effect of the enhancer of zeste homolog 2 (EZH2) inhibitor GSK126 on the proliferation and apoptosis of human tongue squamous cell carcinoma cells in vitro and explore its related mechanisms in order to obtain insights into the clinical treatment of tongue squamous cell carcinoma. Methods Different concentrations of GSK126 were applied to CAL-27 cells of tongue squamous cell carcinoma, and the effects of drugs on cell proliferation were detected through methyl thiazolyl tetrazolium (MTT) assay, colony formation assay, and 5-ethynyl-2’-deoxyuridine (EdU) fluorescence staining. Hoechst33342 fluorescence staining and the JC-1 method were used in observing apoptosis. The expression levels of extracellular regulated protein kinases (ERK), phospho-extracellular regulated protein kinases (p-ERK), Bax, Bcl-2, and Cleaved caspase-9 in Cal-27 cells were detected through Western blot. Results GSK126 inhibited CAL-27 cell proliferation and promoted apoptosis. GSK126 down-regulated the expression of p-ERK and Bcl-2 and increased the expression of Bax and Cleaved caspase-9 (P<0.05). Conclusion GSK126 can inhibit the proliferation of CAL-27 cells in tongue squamous cell carcinoma and promote its apoptosis, and the related mechanism may be associated with the inhibition of the MEK/ERK signaling pathway and activation of the Bax/Bcl-2 pathway.

Key words: tongue squamous cell carcinoma, GSK126, proliferation, apoptosis

CLC Number:

R739.8

Liu Jianan, Ma Zhaolei, Su Rongjian, Huang Keqiang. Effect of enhancer of zeste homolog 2 inhibitor GSK126 on the proliferation and apoptosis of tongue squamous cell carcinoma[J]. West China Journal of Stomatology, 2020, 38(5): 495-501.

Figures/Tables 7

Fig 1

Fig 2

Fig 3

Fig 4

Fig 5

Tab 1

Fig 6

References 21

[1]	Ferlay J, Colombet M, Soerjomataram I , et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer, 2019,144(8):1941-1953. doi: 10.1002/ijc.31937 URL pmid: 30350310
[2]	Hussein AA, Helder MN, de Visscher JG, et al. Global incidence of oral and oropharynx cancer in patients younger than 45 years versus older patients: a systematic review[J]. Eur J Cancer, 2017,82:115-127. doi: 10.1016/j.ejca.2017.05.026 URL pmid: 28654785
[3]	De Paz D, Kao HK, Huang Y , et al. Prognostic stratification of patients with advanced oral cavity squamous cell carcinoma[J]. Curr Oncol Rep, 2017,19(10):65. doi: 10.1007/s11912-017-0624-3 URL pmid: 28799122
[4]	Kim KH, Roberts CW . Targeting EZH2 in cancer[J]. Nat Med, 2016,22(2):128-134. doi: 10.1038/nm.4036 URL pmid: 26845405
[5]	Li Z, Wang Y, Qiu J , et al. The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer[J]. Oncotarget, 2013,4(12):2532-2549.
[6]	Shen L, Cui J, Liang SM , et al. Update of research on the role of EZH2 in cancer progression[J]. Onco Targets Ther, 2013,6:321-324. doi: 10.2147/OTT.S42453 URL pmid: 23589697
[7]	Huang X, Yan J, Zhang M , et al. Targeting epigenetic crosstalk as a therapeutic strategy for EZH2-aberrant solid tumors[J]. Cell, 2018,175(1):186-199. doi: 10.1016/j.cell.2018.08.058 URL pmid: 30220457
[8]	Almangush A, Coletta RD, Bello IO , et al. A simple novel prognostic model for early stage oral tongue cancer[J]. Int J Oral Maxillofac Surg, 2015,44(2):143-150. doi: 10.1016/j.ijom.2014.10.004 URL pmid: 25457829
[9]	Tang QM, Cheng B, Xie MR , et al. Circadian clock gene bmal1 inhibits tumorigenesis and increases paclitaxel sensitivity in tongue squamous cell carcinoma[J]. Cancer Res, 2017,77(2):532-544. doi: 10.1158/0008-5472.CAN-16-1322 URL pmid: 27821487
[10]	Zeng DL, Liu MX, Pan JX . Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells[J]. Oncotarget, 2017,8(2):3396-3411. doi: 10.18632/oncotarget.13773 URL pmid: 27926488
[11]	Wu C, Jin X, Yang J , et al. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer[J]. Oncotarget, 2016,7(3):3440-3452. doi: 10.18632/oncotarget.6497 URL pmid: 26657505
[12]	Gulati N, Béguelin W, Giulino-Roth L . Enhancer of zeste homolog 2 (EZH2) inhibitors[J]. Leuk Lymphoma, 2018,59(7):1574-1585. doi: 10.1080/10428194.2018.1430795 URL pmid: 29473431
[13]	Koppens MA, Bounova G, Cornelissen-Steijger P , et al. Large variety in a panel of human colon cancer organoids in response to EZH2 inhibition[J]. Oncotarget, 2016,7(43):69816-69828. doi: 10.18632/oncotarget.12002 URL pmid: 27634879
[14]	Deschênes-Simard X, Gaumont-Leclerc MF, Bourdeau V , et al. Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation[J]. Genes Dev, 2013,27(8):900-915. doi: 10.1101/gad.203984.112 URL pmid: 23599344
[15]	Kidger AM, Keyse SM . The regulation of oncogenic Ras/ERK signalling by dual-specificity mitogen activated protein kinase phosphatases(MKPs)[J]. Semin Cell Dev Biol, 2016,50:125-132. doi: 10.1016/j.semcdb.2016.01.009 URL pmid: 26791049
[16]	Chan LP, Liu C, Chiang FY , et al. IL-8 promotes inflammatory mediators and stimulates activation of p38 MAPK/ERK-NF-κB pathway and reduction of JNK in HNSCC[J]. Oncotarget, 2017,8(34):56375-56388. doi: 10.18632/oncotarget.16914 URL pmid: 28915597
[17]	Xu XB, Lai YY, Hua ZC. Apoptosis and apoptotic body: disease message and therapeutic target potentials[J]. Biosci Rep, 2019, 39(1): BSR20180992. doi: 10.1042/BSR20180789 URL pmid: 30606744
[18]	Bonneau B, Ando H, Kawaai K , et al. IRBIT controls apoptosis by interacting with the Bcl-2 homolog, Bcl2l10, and by promoting ER-mitochondria contact[J]. Elife, 2016,5:e19896. doi: 10.7554/eLife.19896 URL pmid: 27995898
[19]	Maes ME, Schlamp CL, Nickells RW . Live-cell imaging to measure BAX recruitment kinetics to mitochondria during apoptosis[J]. PLoS One, 2017,12(9):e0184434. doi: 10.1371/journal.pone.0184434 URL pmid: 28880942
[20]	Li P, Zhou LB, Zhao T , et al. Caspase-9: structure, mechanisms and clinical application[J]. Oncotarget, 2017,8(14):23996-24008. doi: 10.18632/oncotarget.15098 URL pmid: 28177918
[21]	Maes ME, Schlamp CL, Nickells RW . BAX to basics: how the BCL2 gene family controls the death of retinal ganglion cells[J]. Prog Retin Eye Res, 2017,57:1-25. doi: 10.1016/j.preteyeres.2017.01.002 URL pmid: 28064040

浓度/（μmol·L^-1）	ERK	p-ERK	Bax	Bcl-2	Cleaved caspase-9
0	1.842±0.076	1.566±0.103	0.989±0.004	1.359±0.048	0.803±0.020
1	1.873±0.127	1.332±0.068	1.084±0.008	1.037±0.055	0.843±0.031
2.5	1.742±0.084	1.313±0.028	1.102±0.044	1.020±0.043	0.889±0.056
5	1.777±0.037	1.076±0.030	1.113±0.049	0.924±0.082	0.907±0.058
10	1.724±0.031	1.071±0.062	1.146±0.050	0.906±0.072	1.015±0.035
15	1.728±0.055	1.052±0.035	1.242±0.030	0.847±0.095	1.038±0.010
F值	2.075	34.431	15.735	21.346	17.065
P值	0.139	0.000	0.000	0.000	0.000